About: Association between Time to Operation and Pathological Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Association between Time to Operation and Pathological Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Association between Time to Operation and Pathological Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
Creator	Kantor, Olga King, Tari Minami, Christina Mittendorf, Elizabeth Nakhlis, Faina Weiss, Anna
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to surgery (TTS), pathological staging and overall survival (OS). STUDY DESIGN: Patients with DCIS or ER+ cT1-2N0 breast cancer treated 2010-2016 were identified in the National Cancer Database. TTS was recorded. Factors associated with pathological upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy. RESULTS: 378,839 patients were identified. Among those undergoing primary surgery, TTS was within 120 days in >98% in all groups. Among cT1-2N0 patients selected for NET, surgery was performed within 120 days in 59.6% of cT1N0 and 30.9% of cT2N0 patients. Increased TTS was associated with increased odds of pathological upstaging in DCIS patients (ER+: 60-120 days: OR:1.15, 95% CI:1.08-1.22; >120 days: OR:1.44, 95% CI:1.24-1.68; ER-: 60-120 days: NS; >120 days: OR:1.36, 95% CI:1.01-1.82; <60 days: reference), but not in patients with invasive cancer irrespective of initial treatment strategy. No difference in OS was seen by TTS in DCIS or NET patients. CONCLUSION: Increased TTS was associated with a small increase in pathological upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic.
has issue date	2020-08-06(xsd:dateTime)
bibo:doi	10.1016/j.jamcollsurg.2020.06.021
bibo:pmid	32771654
has license	no-cc
sha1sum (hex)	b4c410c8b776f2bee7b094c4302139f8b12ed7e5
schema:url	https://doi.org/10.1016/j.jamcollsurg.2020.06.021
resource representing a document's title	Association between Time to Operation and Pathological Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
has PubMed Central identifier	PMC7409804
has PubMed identifier	32771654
schema:publication	J Am Coll Surg
resource representing a document's body	covid:b4c410c8b776f2bee7b094c4302139f8b12ed7e5#body_text
is schema:about of	named entity 'Carcinoma' named entity 'Operation' named entity 'Oncology' named entity 'DCIS' named entity 'Hispanic' named entity 'SPSS' named entity 'ER+' named entity 'pathology' named entity 'breast cancer' named entity 'DCIS' named entity 'DCIS' named entity 'decision-making' named entity '57.7%' named entity 'ER+' named entity 'DCIS' named entity 'ER+' named entity 'COVID-19 pandemic' named entity 'neoadjuvant chemotherapy' named entity 'DCIS' named entity 'ER+' named entity 'selection bias' named entity 'DCIS' named entity 'outcome measure' named entity 'tumor' named entity 'ER+' named entity 'survival rates' named entity 'DCIS' named entity 'pathological staging' named entity 'pathology' named entity 'DCIS' named entity 'surgical pathology' named entity 'neoadjuvant' named entity 'breast surgery' named entity 'chemotherapy' named entity 'DCIS' named entity 'pathological staging' named entity 'ER+' named entity 'mastectomy' named entity 'toxicity' named entity 'outcome measure' named entity 'endocrine therapy' named entity 'neoadjuvant chemotherapy' named entity 'American Joint Committee on Cancer' named entity 'early-stage' named entity 'Breast Cancer' named entity 'multivariable analysis' named entity 'Cox proportional hazards models' named entity 'ER+' named entity 'endocrine therapy' named entity 'random effect' named entity 'private insurance' named entity 'endocrine therapy' named entity 'DCIS' named entity 'zip code' named entity 'Cancer Staging' named entity 'tumor grade' named entity 'COVID-19 pandemic' named entity 'pathology' named entity 'statistically significant' named entity 'endocrine therapy' named entity 'comorbidity' named entity 'DCIS' named entity 'DCIS' named entity 'Hispanic' named entity 'lobular' named entity 'early-stage' named entity 'post-menopausal' named entity 'estrogen receptor' named entity 'AJCC' named entity 'mastectomy' named entity 'early-stage' named entity 'endocrine therapy' named entity 'tumor response' named entity 'breast cancer' named entity 'DCIS' named entity 'logistic regression model'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software